OBJECTIVE: To assess the costs associated with the provision of services for the prevention of mother-to-child transmission (PMTCT) of human immunodeficiency virus in two African countries. METHODS: In 2009, the costs to health-care providers of providing comprehensive PMTCT services were assessed in 20 public health facilities in Namibia and Rwanda. Information on prices and on the total amount of each service provided was collected at the national level. The costs of maternal testing and counselling, male partner testing, CD4+ T-lymphocyte (CD4+ cell) counts, antiretroviral prophylaxis and treatment, community-based activities, contraception for 2 years postpartum and early infant diagnosis were estimated in United States dollars (US$). FINDINGS: The estimated costs to the providers of PMTCT, for each mother-infant pair, were US$202.75-1029.55 in Namibia and US$94.14-342.35 in Rwanda. These costs varied with the drug regimen employed. At 2009 coverage levels, the maximal estimates of the national costs of PMTCT were US$3.15 million in Namibia and US$7.04 million in Rwanda (or < US$0.75 per capita in both countries). Adult testing and counselling accounted for the highest proportions of the national costs (37% and 74% in Namibia and Rwanda, respectively), followed by management and supervision. Treatment and prophylaxis accounted for less than 20% of the costs of PMTCT in both study countries. CONCLUSION: The costs involved in the PMTCT of HIV varied widely between study countries and in accordance with the protocols used. However, since per-capita costs were relatively low, the scaling up of PMTCT services in Namibia and Rwanda should be possible.
OBJECTIVE: To assess the costs associated with the provision of services for the prevention of mother-to-child transmission (PMTCT) of human immunodeficiency virus in two African countries. METHODS: In 2009, the costs to health-care providers of providing comprehensive PMTCT services were assessed in 20 public health facilities in Namibia and Rwanda. Information on prices and on the total amount of each service provided was collected at the national level. The costs of maternal testing and counselling, male partner testing, CD4+ T-lymphocyte (CD4+ cell) counts, antiretroviral prophylaxis and treatment, community-based activities, contraception for 2 years postpartum and early infant diagnosis were estimated in United States dollars (US$). FINDINGS: The estimated costs to the providers of PMTCT, for each mother-infant pair, were US$202.75-1029.55 in Namibia and US$94.14-342.35 in Rwanda. These costs varied with the drug regimen employed. At 2009 coverage levels, the maximal estimates of the national costs of PMTCT were US$3.15 million in Namibia and US$7.04 million in Rwanda (or < US$0.75 per capita in both countries). Adult testing and counselling accounted for the highest proportions of the national costs (37% and 74% in Namibia and Rwanda, respectively), followed by management and supervision. Treatment and prophylaxis accounted for less than 20% of the costs of PMTCT in both study countries. CONCLUSION: The costs involved in the PMTCT of HIV varied widely between study countries and in accordance with the protocols used. However, since per-capita costs were relatively low, the scaling up of PMTCT services in Namibia and Rwanda should be possible.
Authors: Patrick A Coffie; Serge K Kanhon; Hapsatou Touré; Virginie Ettiegne-Traoré; Elizabeth Stringer; Jeff S Stringer; François Dabis; Didier K Ekouevi Journal: J Acquir Immune Defic Syndr Date: 2011-07-01 Impact factor: 3.731
Authors: Zulfiqar A Bhutta; Mickey Chopra; Henrik Axelson; Peter Berman; Ties Boerma; Jennifer Bryce; Flavia Bustreo; Eleonora Cavagnero; Giorgio Cometto; Bernadette Daelmans; Andres de Francisco; Helga Fogstad; Neeru Gupta; Laura Laski; Joy Lawn; Blerta Maliqi; Elizabeth Mason; Catherine Pitt; Jennifer Requejo; Ann Starrs; Cesar G Victora; Tessa Wardlaw Journal: Lancet Date: 2010-06-05 Impact factor: 79.321
Authors: Elizabeth M Stringer; Didier K Ekouevi; David Coetzee; Pius M Tih; Tracy L Creek; Kathryn Stinson; Mark J Giganti; Thomas K Welty; Namwinga Chintu; Benjamin H Chi; Catherine M Wilfert; Nathan Shaffer; Francois Dabis; Jeffrey S A Stringer Journal: JAMA Date: 2010-07-21 Impact factor: 56.272
Authors: I Ochoa-Moreno; S Bautista-Arredondo; S I McCoy; R Buzdugan; C Mangenah; N S Padian; F M Cowan Journal: PLoS One Date: 2020-05-20 Impact factor: 3.240
Authors: Aggrey D Mukose; Senait Kebede; Christine Muhumuza; Fredrick Makumbi; Henry Komakech; Esther Bayiga; Denis Busobozi; Joshua Musinguzi; Andreas Kuznik; Peter Stegman; Steven Forsythe; Joseph Kagaayi Journal: Biomed Res Int Date: 2020-05-18 Impact factor: 3.411
Authors: Daniel L D Freitas; Ana F S Peres; Lidiane G Silva; João V M Mariz; Marcos G Santos; Rayanne S P Morais; Camilo L M Morais; Francis L Martin; Daniel A V Pascoal; Juliana D de A S Camargo; Janaina C O Crispim; Kassio M G Lima Journal: Sci Rep Date: 2021-11-19 Impact factor: 4.379
Authors: Kira Elsbernd; Karl M F Emmert-Fees; Amanda Erbe; Veronica Ottobrino; Arne Kroidl; Till Bärnighausen; Benjamin P Geisler; Stefan Kohler Journal: Infect Dis Poverty Date: 2022-07-15 Impact factor: 10.485
Authors: Sergio Bautista-Arredondo; Sandra G Sosa-Rubí; Marjorie Opuni; David Contreras-Loya; Ada Kwan; Claire Chaumont; Abson Chompolola; Jeanine Condo; Omar Galárraga; Neil Martinson; Felix Masiye; Sabin Nsanzimana; Ivan Ochoa-Moreno; Richard Wamai; Joseph Wang'ombe Journal: AIDS Date: 2016-10-23 Impact factor: 4.177